(Q37542909)

20 August 2017

1 reference

title

Hepatitis B virus variants (English)

1 reference

20 August 2017

1 reference

0 references

1 reference

Watcharasak Chotiyaputta

series ordinal

1

1 reference

20 August 2017

Anna S F Lok

series ordinal

2

1 reference

20 August 2017

language of work or name

English

0 references

publication date

7 July 2009

1 reference

Nature Reviews Gastroenterology & Hepatology

20 August 2017

published in

1 reference

20 August 2017

volume

6

1 reference

20 August 2017

issue

8

1 reference

20 August 2017

page(s)

453-462

1 reference

Expression of hepatitis B viral core region in mammalian cells

20 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.107

Wild-type levels of pregenomic RNA and replication but reduced pre-C RNA and e-antigen synthesis of hepatitis B virus with C(1653) --> T, A(1762) --> T and G(1764) --> A mutations in the core promoter

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.107

Hepatitis B virus strains with mutations in the core promoter in patients with fulminant hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.107

Long-term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.107

Replication of the genome of a hepatitis B-like virus by reverse transcription of an RNA intermediate

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.107

Viral dynamics in hepatitis B virus infection

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.107

Mutation rate of the hepadnavirus genome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.107

Molecular virology and the development of resistant mutants: implications for therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.107

Hepatitis B virus gene function: the precore region targets the core antigen to cellular membranes and causes the secretion of the e antigen

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.107

Is a function of the secreted hepatitis B e antigen to induce immunologic tolerance in utero?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.107

Mutation preventing formation of hepatitis B e antigen in patients with chronic hepatitis B infection.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.107

Relationship of serological subtype, basic core promoter and precore mutations to genotypes/subgenotypes of hepatitis B virus.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.107

Mutations in the pre-core region of hepatitis B virus serve to enhance the stability of the secondary structure of the pre-genome encapsidation signal

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.107

Hepatitis B virus genotypes in the United States: results of a nationwide study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.107

Prevalence of HBV precore/core promoter variants in the United States

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.107

Exploring the biological basis of hepatitis B e antigen in hepatitis B virus infection

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.107

Associations between hepatitis B virus genotype and mutants and the risk of hepatocellular carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.107

Genome replication, virion secretion, and e antigen expression of naturally occurring hepatitis B virus core promoter mutants.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.107

Different hepatitis B virus genotypes are associated with different mutations in the core promoter and precore regions during hepatitis B e antigen seroconversion

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.107

Hepatic necroinflammation and fibrosis in patients with genotypes Ba and C, core-promoter and precore mutations.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.107

Basal core-promoter mutant of hepatitis B virus and progression of liver disease in hepatitis B e antigen-negative chronic hepatitis B.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.107

Role of hepatitis B virus genotypes Ba and C, core promoter and precore mutations on hepatocellular carcinoma: a case control study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.107

Basal core promoter mutations of hepatitis B virus increase the risk of hepatocellular carcinoma in hepatitis B carriers.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.107

High prevalence of 1762(T) 1764(A) mutations in the basic core promoter of hepatitis B virus isolated from black Africans with hepatocellular carcinoma compared with asymptomatic carriers.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.107

World-wide epidemiology of HBeAg-negative chronic hepatitis B and associated precore and core promoter variants

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.107

Characteristics of patients with chronic hepatitis B in France: predominant frequency of HBe antigen negative cases.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.107

Epidemiological and clinical burden of chronic hepatitis B virus/hepatitis C virus infection. A multicenter Italian study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.107

Hepatitis B e antigen-negative chronic hepatitis B: natural history and treatment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.107

Hepatitis B e antigen-negative chronic hepatitis B in Hong Kong

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.107

HBeAg-negative chronic hepatitis B: from obscurity to prominence

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.107

Hepatitis B virus unable to secrete e antigen and response to interferon in chronic hepatitis B.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.107

Precore stop mutant in HBeAg-positive patients with chronic hepatitis B: clinical characteristics and correlation with the course of HBeAg-to-anti-HBe seroconversion

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.107

Effect of the G1896A precore mutation on drug sensitivity and replication yield of lamivudine-resistant HBV in vitro

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.107

Sustained hepatitis B e antigen seroconversion in patients with chronic hepatitis B after adefovir dipivoxil treatment: analysis of precore and basal core promoter mutants

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.107

Antiviral drug-resistant HBV: standardization of nomenclature and assays and recommendations for management

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.107

Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.107

Inhibitory activity of dioxolane purine analogs on wild-type and lamivudine-resistant mutants of hepadnaviruses

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.107

Entecavir resistance is rare in nucleoside naïve patients with hepatitis B

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.107

Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.107

Hepatitis B virus DNA levels at week 4 of lamivudine treatment predict the 5-year ideal response

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.107

2-Year GLOBE trial results: telbivudine Is superior to lamivudine in patients with chronic hepatitis B.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.107

Report of an international workshop: Roadmap for management of patients receiving oral therapy for chronic hepatitis B.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.107

Virologic monitoring of hepatitis B virus therapy in clinical trials and practice: recommendations for a standardized approach

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.107

Week 48 resistance surveillance in two phase 3 clinical studies of adefovir dipivoxil for chronic hepatitis B.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.107

Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.107

Long-term safety of lamivudine treatment in patients with chronic hepatitis B.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.107

Histological outcome during long-term lamivudine therapy.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.107

Sensitive line probe assay that simultaneously detects mutations conveying resistance to lamivudine and adefovir.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.107

Sensitivity and accuracy of an updated line probe assay (HBV DR v.3) in detecting mutations associated with hepatitis B antiviral resistance

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.107

Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.107

Use of massively parallel ultradeep pyrosequencing to characterize the genetic diversity of hepatitis B virus in drug-resistant and drug-naive patients and to detect minor variants in reverse transcriptase and hepatitis B S antigen

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.107

Predominance of hepatitis B virus YMDD mutants is prognostic of viral DNA breakthrough

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.107

The polymerase L528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistance

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.107

The hepatitis B virus polymerase mutation rtV173L is selected during lamivudine therapy and enhances viral replication in vitro.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.107

Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.107

Selection of a hepatitis B virus strain resistant to adefovir in a liver transplantation patient.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.107

Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.107

Resistance to adefovir dipivoxil in lamivudine resistant chronic hepatitis B patients treated with adefovir dipivoxil

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.107

Low resistance to adefovir combined with lamivudine: a 3-year study of 145 lamivudine-resistant hepatitis B patients.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.107

Variant of hepatitis B virus with primary resistance to adefovir

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.107

Hepatitis B virus containing the I233V mutation in the polymerase reverse-transcriptase domain remains sensitive to inhibition by adefovir

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.107

Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to Lamivudine

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.107

Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.107

Intracellular metabolism and in vitro activity of tenofovir against hepatitis B virus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.107

The rtA194T polymerase mutation impacts viral replication and susceptibility to tenofovir in hepatitis B e antigen-positive and hepatitis B e antigen-negative hepatitis B virus strains

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.107

Selection of a multiple drug-resistant hepatitis B virus strain in a liver-transplanted patient.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.107

Evolution of multi-drug resistant hepatitis B virus during sequential therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.107

Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.107

Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.107

Lamivudine compared with lamivudine and adefovir dipivoxil for the treatment of HBeAg-positive chronic hepatitis B.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.107

Adefovir rapidly suppresses hepatitis B in HBeAg-negative patients developing genotypic resistance to lamivudine.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.107

Tenofovir monotherapy is effective in hepatitis B patients with antiviral treatment failure to adefovir in the absence of adefovir-resistant mutations

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.107

Reduced antigenicity of the hepatitis B virus HBsAg protein arising as a consequence of sequence changes in the overlapping polymerase gene that are selected by lamivudine therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.107

The antiviral drug selected hepatitis B virus rtA181T/sW172* mutant has a dominant negative secretion defect and alters the typical profile of viral rebound

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.107

The concept of hepatitis B virus mutant escape

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.107

Hepatitis B virus mutants: an overview

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.107

Surface gene mutants of hepatitis B virus in infants who develop acute or chronic infections despite immunoprophylaxis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.107

Vaccine-induced escape mutant of hepatitis B virus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.107

Breakthrough infections and identification of a viral variant in Gambian children immunized with hepatitis B vaccine

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.107

Survey of hepatitis B surface variant infection in children 15 years after a nationwide vaccination programme in Taiwan.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.107

Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.107

Hepatitis B virus envelope variation after transplantation with and without hepatitis B immune globulin prophylaxis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.107

Hepatitis B virus surface mutations associated with infection after liver transplantation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.107

Hepatitis B virus S mutants in liver transplant recipients who were reinfected despite hepatitis B immune globulin prophylaxis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.107

Liver transplantation in European patients with the hepatitis B surface antigen

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.107

Lamivudine plus low-dose hepatitis B immunoglobulin to prevent recurrent hepatitis B following liver transplantation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.107

Hepatitis B virus genotype A rarely circulates as an HBe-minus mutant: possible contribution of a single nucleotide in the precore region.

31 March 2020

1 reference

12 December 2020

Effects of a naturally occurring mutation in the hepatitis B virus basal core promoter on precore gene expression and viral replication

1 reference

12 December 2020

Selection of hepatitis B virus polymerase mutations in HIV-coinfected patients treated with tenofovir.

1 reference

12 December 2020

Mechanism of viral persistence and resistance to nucleoside and nucleotide analogs in chronic hepatitis B virus infection

1 reference

12 December 2020

Enrichment of a precore-minus mutant of duck hepatitis B virus in experimental mixed infections

1 reference

12 December 2020

Suboptimal response to adefovir dipivoxil therapy for chronic hepatitis B in nucleoside-naive patients is not due to pre-existing drug-resistant mutants.

1 reference

12 December 2020

Evaluation of methods for monitoring drug resistance in chronic hepatitis B patients during lamivudine therapy based on mass spectrometry and reverse hybridization

1 reference

12 December 2020

Predictive value of precore hepatitis B virus mutations in spontaneous and interferon-induced hepatitis B e antigen clearance

1 reference

12 December 2020

10.1038/NRGASTRO.2009.107

Identifiers

DOI

1 reference

20 August 2017

1 reference